Loading…
TriSalus Life Sciences, Inc. is projected to decline to $3.00 by 2027, a -6% move from its current price of $3.19. TLSI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.06 | $3.19 | $3.32 | -0.05% |
| May 30 | $3.00 | $3.19 | $3.38 | -0.11% |
| May 31 | $2.96 | $3.18 | $3.42 | -0.16% |
| Jun 1 | $2.93 | $3.18 | $3.46 | -0.21% |
| Jun 2 | $2.90 | $3.18 | $3.49 | -0.26% |
| Jun 3 | $2.87 | $3.18 | $3.52 | -0.32% |
| Jun 4 | $2.85 | $3.18 | $3.55 | -0.37% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.85 | $3.18 | $3.55 | -0.37% |
| Week 2 | $2.71 | $3.17 | $3.70 | -0.74% |
| Week 3 | $2.61 | $3.15 | $3.82 | -1.10% |
| Week 4 | $2.52 | $3.14 | $3.92 | -1.47% |
| Week 5 | $2.45 | $3.13 | $4.00 | -1.83% |
| Week 6 | $2.38 | $3.12 | $4.08 | -2.19% |
| Week 7 | $2.32 | $3.11 | $4.16 | -2.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
TriSalus Life Sciences, Inc. operates in the Healthcare sector, focusing on research, development, and commercialization of a drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer.
The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It was founded in 2009 and is headquartered in Westminster, Colorado. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff.
TLSI is currently trading at $3.26 with a market capitalization of $200.22M and a market rank of 3847. The current price and market position place it among smaller-cap healthcare peers. The forecast suggests a multi-year path with volatility but a bullish tilt toward the end of the period, culminating in substantially higher averages by 2050.
Across the forecast horizon, the average price trends upward from mid-single digits to the teens by 2050, with the 2030 average at $4.94 and the 2050 average at $14.77. The maximums peak at $33.60 in 2050, reflecting meaningful upside under certain scenarios. These figures imply a long-run upward trajectory, though near-term momentum remains mixed and uncertain.
A major floor 58.5% below — a decisive break under it would weaken the trend.
The nearest floor, 21.0% below — buyers have tended to step in here.
The nearest ceiling, 45.8% above — a clean break opens room to run.
A major ceiling 75.0% above — clearing it would confirm fresh momentum.
Key TLSI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TLSI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.27 | Sell | $3.23 | Sell |
| MA 10 | $3.04 | Buy | $3.33 | Sell |
| MA 20 | $3.75 | Sell | $3.60 | Sell |
| MA 50 | $4.03 | Sell | $4.03 | Sell |
| MA 100 | $4.57 | Sell | $4.43 | Sell |
| MA 200 | $4.93 | Sell | $4.77 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.22 | Neutral |
| Stoch RSI (14) | 52.54 | Neutral |
| CCI (20) | -52.64 | Neutral |
| Williams %R (14) | -67.16 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -27.99 | Sell |
| Bollinger %B (20,2) | 0.31 | Neutral |
| Stochastic %K (14) | 32.84 | Neutral |
| TRIX (15) | -0.96 | Sell |
| Awesome (5,34) | -0.78 | Sell |
| Ultimate (7,14,28) | 56.57 | Neutral |
| Momentum (10) | -1.37 | Sell |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 3.35 | Sell |
| ADX (14) | 22.00 | Sell |
| ATR (14) | 0.18 | Info |
The 30-day technical picture is Bearish. The RSI14 sits at 40, signaling room for movement but not oversold conditions, and the price remains below both the 50-day and 200-day moving averages: SMA50 is $4.06 and SMA200 is $4.94.
Price action is bounded by a 30-day range from $2.44 to $4.36, with a nearby support at $2.52 and a resistance at $4.65. These levels suggest limited upside against ongoing downside pressure in the near term.
Annualized volatility is high at 80%, underscoring the sharper swings typical of small-cap healthcare names.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.52 | $3.19 | $3.92 | 0% | Neutral | |
| $2.26 | $3.00 | $4.29 | -6% | Neutral | |
| $2.54 | $3.52 | $5.29 | +10% | Neutral | |
| $3.02 | $4.35 | $6.79 | +36% | Bullish | |
| $3.18 | $4.73 | $7.63 | +48% | Bullish | |
| $2.97 | $4.56 | $7.56 | +43% | Bullish | |
| $3.02 | $4.78 | $8.15 | +50% | Bullish | |
| $2.89 | $4.71 | $8.20 | +48% | Bullish | |
| $2.75 | $4.60 | $8.19 | +44% | Bullish | |
| $3.76 | $6.44 | $11.69 | +102% | Bullish | |
| $3.66 | $7.08 | $13.94 | +122% | Bullish | |
| $6.24 | $13.87 | $30.63 | +335% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.52 | $3.19 | $3.77 | +0.00% |
| June 2026 | $2.59 | $3.08 | $3.76 | -3.60% |
| July 2026 | $2.53 | $3.04 | $3.80 | -1.14% |
| August 2026 | $2.59 | $3.15 | $4.00 | +3.75% |
| September 2026 | $2.52 | $3.09 | $3.97 | -2.04% |
| October 2026 | $2.34 | $2.89 | $3.76 | -6.41% |
| November 2026 | $2.33 | $2.89 | $3.79 | +0.07% |
| December 2026 | $2.37 | $2.97 | $3.92 | +2.49% |
Click any year to see its month-by-month TLSI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
TriSalus Life Sciences, Inc.'s 2026 outlook centres on $3.19, within a $2.52 to $3.92 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, TLSI could reach as high as $4.29, with a base case around $3.00 and support toward $2.26 — roughly -6% from $3.19. Price action looks broadly range-bound.
Expect TLSI to range from $2.54 to $5.29 through 2028. The $3.52 average target implies a +10% move from current prices. That is up +17% on the projected 2027 average. A consolidation phase looks the most probable path here.
The TLSI price prediction for 2029 points to an average of $4.35 (low $3.02, high $6.79) — a potential gain of +36% on today's $3.19. Momentum favours further upside here.
In 2030, TLSI is projected to trade between $3.18 and $7.63, averaging $4.73 — a potential gain of +48% from today's $3.19. That is up +9% on the projected 2029 average. Buyers look set to stay in control over this stretch.
TriSalus Life Sciences, Inc.'s 2031 outlook centres on $4.56, within a $2.97 to $7.56 range. That is -4% versus the projected 2030 average. That marks a +43% change versus current levels. Momentum favours further upside here.
By 2032, TLSI could reach as high as $8.15, with a base case around $4.78 and support toward $3.02 — roughly +50% from $3.19. Buyers look set to stay in control over this stretch.
Expect TLSI to range from $2.89 to $8.20 through 2033. The $4.71 average target implies a +48% move from current prices. That is -2% versus the projected 2032 average. Momentum favours further upside here.
The TLSI price prediction for 2034 points to an average of $4.60 (low $2.75, high $8.19) — a potential gain of +44% on today's $3.19. Buyers look set to stay in control over this stretch.
In 2035, TLSI is projected to trade between $3.76 and $11.69, averaging $6.44 — a potential gain of +102% from today's $3.19. That is up +40% on the projected 2034 average. Momentum favours further upside here.
TriSalus Life Sciences, Inc.'s 2040 outlook centres on $7.08, within a $3.66 to $13.94 range. That is up +10% on the projected 2035 average. That marks a +122% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, TLSI could reach as high as $30.63, with a base case around $13.87 and support toward $6.24 — roughly +335% from $3.19. Momentum favours further upside here.
Investing $1,000 in TLSI today (≈ 313.479624 TLSI) could be worth
$4,346.47
+$3,346.47 (+335%) by 2050 · US Dollar
Based on the average projected TLSI price of $13.87 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TLSIwould be worth at today's price.
$1,000 invested in TLSI on May 27, 2025 (≈ 178.890872 TLSI) would be worth
$570.66
-$429.34 (-42.9%) today · 0.57× · US Dollar
Based on a TLSI entry price of $5.59 vs. today's $3.19.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.24 | $984.57 | -1.5% |
| 1 month ago | $4.5 | $708.89 | -29.1% |
| 3 months ago | $5.38 | $592.94 | -40.7% |
| 6 months ago | $6.87 | $464.34 | -53.6% |
| 1 year ago | $5.59 | $570.66 | -42.9% |
| All time (5.0y) ago | $9.7 | $328.87 | -67.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TLSI forecast.
Our base-case forecast reaches $6.40 around 2035.
Implied market cap at $6.40: $393.07M
The year-by-year forecast shows a path from neutral to bullish as time progresses. For 2026, the average price is $3.26 with a min of $2.52 and a max of $4.02; the ROI is 0 and sentiment is NEUTRAL.
In 2027, the min is $2.27, the avg is $3.05, the max is $4.40; ROI is -6.5 and sentiment NEUTRAL. In 2028, the min is $2.65, the avg is $3.72, the max is $5.67; ROI 14.1 and sentiment NEUTRAL. In 2029, the min is $3.12, the avg is $4.57, the max is $7.25; ROI 40.2 and sentiment BULLISH.
For 2030, the average reaches $4.94 with a min of $3.25 and a max of $8.11; ROI is 51.4 and sentiment BULLISH. 2031 shows avg $4.83, min $3.08, max $8.17; ROI 48 and sentiment BULLISH. 2032 shows avg $5.00, min $3.09, max $8.69; ROI 53.4 and sentiment BULLISH.
2033 shows avg $4.89, min $2.93, max $8.70; ROI 49.9 and sentiment BULLISH. 2034 shows avg $4.90, min $2.85, max $8.91; ROI 50.2 and sentiment BULLISH.
2035 carries a stronger upturn with avg $6.91, min $3.91, max $12.83; ROI 112.1 and sentiment BULLISH. 2040 shows avg $7.63, min $3.77, max $15.41; ROI 134.1 and sentiment BULLISH. By 2050, the average is $14.77 with a min of $6.65 and a max of $33.60; ROI 353.2 and sentiment BULLISH.
These figures are estimates and not guarantees, and actual results will depend on a range of market and firm-specific factors.
Tap a question to reveal the answer.
In 2030, the average price is $4.94 with a min of $3.25 and a max of $8.11; ROI is 51.4 and sentiment BULLISH.
Near term shows neutral sentiment in 2026 and 2027 with gradual upside in later years. The 2030 average is $4.94 with ROI 51.4 and bullish sentiment; by 2050 the average is $14.77 with ROI 353.2 and bullish sentiment.
The forecast shows higher potential later in the horizon, with 2040 max $15.41 and 2050 max $33.60, and 2035 max $12.83. This indicates the possibility of clearing $10 in those periods, though these are not guarantees.
Current price: $3.26.
For 2029, the min is $3.12, the average is $4.57, the max is $7.25; ROI is 40.2 and sentiment is BULLISH.
TriSalus Life Sciences, Inc. Community Discussion
0Share your TriSalus Life Sciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.